BIOMARIN PHARMACEUTICAL INC Cash and Restricted Cash
BIOMARIN PHARMACEUTICAL INC (BMRN) had Cash and Restricted Cash of $874.00 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $874.00M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $3.07B.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.31B.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.25B.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $874.00M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $3.07B 10-Q · filed 2026-05-05 |
| 2025-12-31 | $1.31B 10-Q · filed 2026-08-06 |
| 2025-09-30 | $1.25B 10-Q · filed 2025-10-28 |
| 2025-06-30 | $1.21B 10-Q · filed 2026-08-06 |
| 2025-03-31 | $1.05B 10-Q · filed 2026-05-05 |
| 2024-12-31 | $942.84M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $675.45M 10-Q · filed 2025-10-28 |
| 2024-06-30 | $972.15M 10-Q · filed 2025-08-05 |
| 2024-03-31 | $747.00M 10-Q · filed 2025-05-02 |
| 2023-12-31 | $755.13M 10-K · filed 2026-02-26 |
| 2023-09-30 | $785.41M 10-Q · filed 2024-10-31 |
| 2023-06-30 | $694.38M 10-Q · filed 2024-08-05 |
| 2023-03-31 | $580.07M 10-Q · filed 2024-04-26 |
| 2022-12-31 | $724.53M 10-K · filed 2026-02-26 |
| 2022-09-30 | $761.51M 10-Q · filed 2023-11-02 |
| 2022-06-30 | $619.80M 10-Q · filed 2023-08-02 |
| 2022-03-31 | $605.44M 10-Q · filed 2023-04-28 |
| 2021-12-31 | $587.28M 10-K · filed 2025-02-24 |
| 2021-09-30 | $617.14M 10-Q · filed 2022-10-28 |
| 2021-06-30 | $641.53M 10-Q · filed 2022-08-04 |
| 2021-03-31 | $667.31M 10-Q · filed 2022-04-29 |
| 2020-12-31 | $649.16M 10-K · filed 2024-02-26 |
| 2020-09-30 | $1.02B 10-Q · filed 2021-10-29 |
| 2020-06-30 | $818.90M 10-Q · filed 2021-07-30 |
| 2020-03-31 | $476.63M 10-Q · filed 2021-04-30 |
| 2019-12-31 | $437.45M 10-K · filed 2023-02-27 |
| 2019-09-30 | $423.22M 10-Q · filed 2020-11-06 |
| 2018-12-31 | $493.98M 10-K · filed 2022-02-25 |
| 2017-12-31 | $598.03M 10-K · filed 2021-02-26 |
| 2016-12-31 | $408.33M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |